Connect your AI

Anika Therapeutics ANIK Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

AVN

AVNSAVNS

$1.3M-40.9%

Globus MedicalGMED

——

Other financials

Income statement

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Balance sheet

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Cash flow

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Valuation

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Profitability

Net margin-3.4%-1.6pp

FCF margin0.5%—

Returns & leverage

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's payments for repurchase of common stock?: Anika Therapeutics (ANIK) reported payments for repurchase of common stock of $853K in Q2 2026.